Taysha Gene Therapies
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 52
- Market Cap
- $438.5M
- Website
- http://www.tayshagtx.com
Safety and Efficacy of TSHA-102 in Pediatric Females With Rett Syndrome (REVEAL Pediatric Study)
Phase 1
Recruiting
- Conditions
- Rett Syndrome
- Interventions
- Genetic: TSHA-102
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- Taysha Gene Therapies, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT06152237
- Locations
- 🇺🇸
University of California San Diego (UCSD), La Jolla, California, United States
🇺🇸Rush University Medical Center & Children's Hospital, Chicago, Illinois, United States
🇺🇸Boston Children's at Brookline, Boston, Massachusetts, United States
Safety and Efficacy of TSHA-102 in Adolescent and Adult Females with Rett Syndrome (REVEAL Adult Study)
Phase 1
Recruiting
- Conditions
- Rett Syndrome
- Interventions
- Genetic: TSHA-102
- First Posted Date
- 2022-11-07
- Last Posted Date
- 2024-11-13
- Lead Sponsor
- Taysha Gene Therapies, Inc.
- Target Recruit Count
- 18
- Registration Number
- NCT05606614
- Locations
- 🇨🇦
CHU St. Justine, Montréal, Quebec, Canada
🇺🇸UC San Diego, La Jolla, California, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
A Study of the Natural Course of SURF1 Deficiency
Withdrawn
- Conditions
- Leigh Syndrome
- Interventions
- Other: None (Observational study)
- First Posted Date
- 2022-03-14
- Last Posted Date
- 2022-05-20
- Lead Sponsor
- Taysha Gene Therapies, Inc.
- Registration Number
- NCT05277363
- Locations
- 🇺🇸
UTSW Medical Center at Dallas, Dallas, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath